Quantoom Biosciences, is reinventing mRNA production by developing an RNA Platform that encompasses DNA and RNA manufacturing and formulation, along with critical reagent supply, from sequence to large scale production. Quantoom’s approach to the production of mRNA vaccines involves redesigning the entire manufacturing process from start to finish. By doing this, Quantoom Biosciences can produce mRNA vaccines faster, more efficiently, and at a lower cost than traditional methods. | Quantoom Biosciences is a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Its N-Force toolbox relies on 3 core elements to turn any antigen into a (sa)mRNA-LNP drug product: Ncode for sequence design and optimization, Ntensify® for RNA production and NcapsulateTM for RNA-LNP formulation. Launched in 2023, the Ntensify solution enables fully integrated, scalable RNA production by combining processes, equipment, reagent mixes, and disposables and has gained global adoption, being recognized for performance and ease-of-use. Beyond technology, Quantoom Biosciences assists its partners by providing extensive enabling solutions, ranging from strategic R&D partnerships to sequence design & optimization.
PrecisemAb Biotech Co., Ltd.
PrecisemAb is a spin-off startup of Kaohsiung Medical University. Its core technology, Universal Antibody Lock, can significantly reduce side effects caused by antibody drugs, making antibody therapy safe and effective. [Features of Core Technology (Antibody Lock)] ‧Higher masking ability and removal ability ‧Low immunogenicity ‧Prevention of anti-drug antibody binding ‧Prolonged serum half-life [Lead Product] PSM101, the lead candidate for head and neck cancer and colorectal cancer treatment, will complete stable cell clone generation in 2023 and the non-human primate side effect test in 2024-Q1. [Partnering] Through the (1) co-development of Lock-antibodies and (2) customized Antibody Lock design service, PrecisemAb licenses out Lock-antibodies to global pharma for conducting further clinical trials. | PrecisemAb is a spin-off startup of Kaohsiung Medical University. Its core technology, Universal Antibody Lock, allows antibody drugs, including ADC and bispecific antibodies, to take effect only in diseased areas, solving systemic toxicity and making antibody treatment safe and effective. Now, we are developing the first-in-class antibody drug, PSM101, for advanced head and neck cancer. [Features of Antibody Lock] ★Medication safety with minimized adverse effects ★Elevating treatment efficacy for cancer cure ★Precision-designed for targeting various cancers [Partnering] PrecisemAb licenses Lock-antibodies for further clinical trials through: (1) Co-development of Lock-antibodies: [Oncology] Lock-EGFR, Lock-PD1, Lock-CTLA4, Lock-4-1BB [Autoimmune disease] Lock-TNFα, Lock-IL-1β (2) Customized Antibody Lock Design Service: Including 4 steps to design your own Lock-antibody. | Company Overview Founded in October 2021, PrecisemAb Biotech was established by the late Professor Tian-Lu Cheng, former Vice President of Kaohsiung Medical University (KMU), as a KMU spin-off company. PrecisemAb focuses on applying the exclusively licensed Universal Antibody Lock Technology to develop next-generation precision antibody drugs with high specificity, low side effects, and enhanced therapeutic efficacy. Innovations & Advantages of the Universal Antibody Lock Platform The Universal Antibody Lock Technology integrates a Hinge + Linker structure that connects the VL/VH domains of an antibody. This unique design prevents antibodies from binding to healthy tissues until they reach the tumor microenvironment (TME). The Hinge-based lock, derived from human IgG1, serves as a masking mechanism, reducing unwanted interactions with normal tissues. The Linker, optimized through computational modeling, includes tumor-specific protease cleavage sites and spatial adjustment regions that ensure precise activation in the tumor microenvironment (TME). This mechanism enables antibodies to remain inactive in normal tissues and only activate when exposed to tumor-specific proteases, thereby minimizing off-target toxicity and enhancing therapeutic efficacy. By selectively triggering antibody activation at the tumor site, this technology significantly reduces side effects and improves treatment outcomes, ultimately enhancing patient quality of life. Compared to competing platforms, the Universal Antibody Lock Technology offers several key advantages. First, the human IgG1 hinge-based lock has low immunogenicity, reducing the risk of anti-drug antibody (ADA) formation and avoiding interference with drug efficacy. Second, the platform is highly versatile, allowing seamless integration into monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and bispecific antibodies (BsAbs), which accelerates the development timeline for Lock-antibody drugs. Third, the linker design, incorporating tumor-specific protease cleavage sites and spatial adjustment regions, delivers the highest antibody activation rate globally in TME. The Universal Antibody Lock Technology has been adopted for industry collaboration. In May 2024, GlycoNex Biotech signed a non-exclusive licensing agreement with PrecisemAb, further demonstrating its applicability in antibody drug development. Drug Development (1) PrecisemAb’s lead drug, PSM101 (Lock-EGFR antibody), is designed for EGFR-expressing cancers, including head and neck cancer and colorectal cancer. The drug has successfully completed in vitro and in vivo efficacy and safety studies, cell line development, upstream process optimization (yield: 4.2 g/L), downstream process optimization, formulation research, and accelerated stability testing. PSM101 is planned for IND submission to the US FDA and TFDA in Q4 2026. (2) Additionally, PSM915 (Lock-TNF-α) has been evaluated in Biomedcode’s rheumatoid arthritis (RA) mouse model, demonstrating its ability to suppress RA disease progression and improve drug safety.
ORF Biologics, Inc.
ORF Biologics is a mission-driven, high-impact, Iowa-based biotechnology company advancing the rapid development of next-generation proteins, peptides, antibodies, therapeutics, diagnostics, and vaccines for human and animal health, as well as national defense. Founded by scientists with deep industrial and academic experience, we combine synthetic biology with advanced biomanufacturing to engineer proteins that are difficult to produce yet critically needed. Our capabilities span multiple expression systems paired with a complete bioproduction infrastructure: upstream design, downstream manufacturing and purification, and in-house quality control. This allows us to move quickly from gene to purified protein, supporting programs in infectious disease, neurodegeneration, regenerative medicine, oncology, agriculture and the veterinary industry, biodefense and more. At ORF Biologics, we are redefining what regional biotech can achieve. We specialize in the design and production of custom biologics—tailored proteins and antibodies that meet specific functional, structural, or delivery requirements. Whether it’s producing recombinant viral antigens for diagnostics, growth factors for tissue culture-based modeling and cell therapy, or novel fusion proteins for targeted delivery and therapeutic efficacy using animal models, ORF Biologics matches the right host system and production method to each molecule. Our synthetic biology workflows enable rapid prototyping, codon optimization, secretion tagging, and fusion design, while our modular infrastructure allows for efficient purification and scalability. From difficult-to-express glycoproteins to secreted immune modulators and neuroprotective candidates, we provide full-spectrum support—from DNA construct to quality-controlled protein—in a fraction of the typical development time at a lower cost. We work closely with industry, government, and academic partners to translate urgent needs into quality custom biologics, delivered with speed, precision, and domestic manufacturing independence.
Oklahoma State University
Oklahoma State University is a Tier 1 research university offering a full range of degrees in Engineering, Biotechnology, Agriculture and Medicine | Oklahoma State University is a land grant institution, focused on improving our quality of life by bringing new technologies, processes, research, and medicines to the marketplace. OSU is showcasing several technologies that are at the right stage for partnering at BIO International. Cowboy Enterprises is the orange-plated, premium conduit for Industry and Oklahoma State University engagement. Meeting needs for research, technology transfer, lab & research facilities, research park, as well as mutually beneficial collaborations, Cowboy Enterprises would like to show you how OSU Orange is the answer. Our mission runs parallel with that of Oklahoma State University’s land grant mission of taking university research from “CAMPUS TO COMMUNITY”. Collaborating with research Cowboy Innovations and OSU’s researchers to identify technologies that have commercial interest and viability, and progress them to later stages of development that will meet market needs. The College of Veterinary Medicine is a major research center on campus. We have invested in state of the art laboratory facilities to accomplish our mission of service to companion animal, livestock, and human health and well-being. These laboratories are designed to the highest standards for conduct of infectious disease and toxicology research and meet all federal and state regulatory guidelines. OSU-CHS Tulsa (Center for Health Sciences) has just brought on-line a new facility that is centrally managed for FDA Clinical Trials (non-ontological). OSU-CHS has conducted clinical trials since the early 2000’s with an average of 10 to 15 clinical trials a year. Over the last four years, there have been a total of 16 FDA-regulated clinical trials. It is important to note that the clinical trials range in time frame from 1 to 15 years (thus overlapping between the years for the total number of trials). The OSU-CHS clinical trials unit supports clinical trial operations for our investigators in Tulsa, within our outpatient clinical practice areas. Active clinical trials include Pediatrics, Internal Medicine, and Internal Medicine specialty services (Ryan White Center). Oklahoma Center for Respiratory and Infectious Diseases (OCRID) OCRID is a focal point for expanding respiratory infectious disease research in Oklahoma. OCRID engages in critical research on respiratory infectious diseases with a focus on the influenza virus, respiratory syncytial virus, and respiratory bacterial and fungal infections, and now COVID-19. The interdisciplinary projects in OCRID cover therapeutics, vaccine, diagnostics, disease pathogenesis, nutrition, and bioengineering. OCRID provides training and mentoring to junior faculty and the next-generation of scientists, promotes collaboration among scientists throughout the region, recruits new faculty to member institutions, and strengthens biomedical research infrastructure. Institute for Translational and Emerging Research in Advanced Comparative Therapy (INTERACT) Located in the College of Veterinary Medicine, INTERACT leads the one-health mission of OSU by bringing together clinicians, scientists and researchers involved in fundamental discovery, industry and foundations under one roof. INTERACT is endowed with state-of-the art research and clinical infrastructure, and dedicated personnel. We are currently running several clinical trials. We welcome researchers from across the nation to collaborate and participate in our preclinical projects or clinical trials. The Center for Health Systems Innovation (CHSI) creates solutions to transform patient care with an intensive focus on rural primary care and communities. We design, test, and implement solutions to clearly defined problems in rural primary care clinics and hospital settings. Additionally, CHSI focuses on mental health and its impact on outcomes. The National Center for Wellness and Recovery (NCWR), part of Oklahoma State University Center for Health Services, is a leading medical educator and healthcare provider. Our vision is to eliminate addiction through research and excellence in patient care. The NCWR is looking for partners to advance the treatment and prevention of addiction along with innovative therapies for pain. Rural healthcare providers face patients with more chronic diseases than other populations of the same age. Therefore, we focus on the following diseases: Heart disease, Stroke, Hypertension, Diabetes, Respiratory, and Addiction. Human Performance and Nutrition Research Institute (HPNRI) Oklahoma State University is harnessing the university’s cutting-edge research expertise in human performance and nutrition science, coupling it with advanced knowledge from our elite strength and conditioning staff and leveraging it with leading industry partner relationships to create a first-of-its-kind, university-based research institute. Oklahoma Disease Diagnostic Laboratory (OADDL) Promoting the overall well-being of animal health through veterinary diagnostic testing, instruction of professional students, and research in diseases of economic importance to Oklahoma and beyond. National Center for Veterinary Parasitology Launched in 2009, the National Center for Veterinary Parasitology (NCVP) at Oklahoma State University’s Center for Veterinary Health Sciences is helping carry the fight against parasites and vectors, such as mosquitoes, ticks, and the organisms they transmit. These foes attack humans, animals and our food supply. The National Center for Veterinary Parasitology is the only one of its kind and began with the financial backing of the Kirkpatrick Foundation, Novartis Animal Health, Bayer Animal Health and Merial. Since many of these parasites are zoonotic and can cause disease in people, so identifying and treating the infections are particularly important. The center also provides egg per gram counts for horses and cattle, allowing veterinarians to tailor integrated parasite management programs and monitor treatment effectiveness. Comparative Metabolic Lab The Comparative Metabolism laboratory investigates glucose metabolism during metabolic diseases (e.g., diabetes, insulin resistance and obesity) and novel metabolic therapeutic strategies that could benefit both veterinary and human patients. Diabetes and obesity, global epidemic diseases, are significant risk factors for cardiovascular and pulmonary diseases. One of the major pathogenic processes underlying these metabolic diseases results from a deficit of insulin production or action, with dysfunctional glucose uptake into insulin-sensitive tissues. Core Facilities Genomics and Proteomics Center: Providing DNA and Protein sequencing and genomic and proteomic analyses across the campus. DNA Protein Core Facility: The Facility performs specialized biochemical analysis, manages a battery of multi-user equipment including mass spec, provides technical expertise, and vends specialized biochemicals, to analyze structure and function of DNA and proteins. Oklahoma Statewide Shared Nuclear Magnetic Resonance Facility: NMR is an extremely versatile and robust spectroscopic method for studies of biomolecules in solution. Indeed, this is the only spectroscopic technique that provides detailed structural and dynamic information of a biomolecule in its native environment. The Facility allows users including faculty members, post-doctoral scientists, graduate and undergraduate students in all major academic institutions, 4-year undergraduate colleges as well as scientists working in industries in Oklahoma and the surrounding region (Kansas and Texas) to conduct research investigations. We welcome scientists from all parts of the country to take advantage of this state-of-the-art facility.
NUVISAN
Your partner of choice in bringing therapeutics to life. Nuvisan is a full-service CRO and CDMO with state-of-the-art facilities in Germany and France, supporting pharmaceutical, biotech, venture capital and non-profit partners with high-quality, end-to-end solutions that accelerate the journey from early discovery to clinical development. With more than 40 years of heritage, Nuvisan has built a reputation for scientific excellence, industry expertise and seamless integration across discovery, development and manufacturing. Our centres of excellence, including drug discovery in Berlin, provide comprehensive capabilities to advance complex programs efficiently. In oncology, Nuvisan offers a comprehensive portfolio of specialised technologies and models designed to accelerate cancer therapeutic innovation. Our capabilities encompass target validation, CRISPR/RNAi screening, custom assay development, next-generation sequencing, single-cell analyses, multiplex flow cytometry, biomarker discovery and in vivo pharmacology including PK/PD and efficacy studies. With an extensive collection of cancer models and deep translational expertise, we support programs across solid tumours, hematologic malignancies, immuno-oncology and novel therapeutic modalities. By working collaboratively to adapt to each client’s unique needs, we help de-risk development and expedite the delivery of impactful oncology therapeutics to patients worldwide. | The NUVISAN group is a contract research and development and manufacturing organization (CRO/CDMO) with five sites in Germany and France as well as local experts situated in Latin America. We offer unique, high-quality, and tailored integrated solutions along the drug discovery and development value chain to our biotech startup, pharma, non-profit, and venture capital clients – from target identification to the patient. With over 40 years of experience and a dedicated team of over 1,000 professionals, including more than 70% industry-experienced scientists and laboratory professionals, we possess the expertise to navigate the complexities of bringing innovative medicines to market. Recognizing the unique nature of each project, our teams prioritize flexible and innovative approaches and foster transparent communication to work closely with clients and effectively meet individual needs. | Your partner of choice in bringing therapeutics to life Nuvisan is a full-service contract research organisation (CRO) and development and manufacturing organisation (CDMO) with state-of-the-art laboratories in Germany and France. Our pharmaceutical, biotechnology, venture capital and non-profit clients partner with us because our high-quality end-to-end solutions and scientific expertise enable us to streamline and accelerate drug discovery and development – from ensuring target understanding to helping bring therapeutics to life. Founded over 40 years ago by a team of pharma industry innovators, Nuvisan has established a reputation for expertise and professionalism. Our team leaders have extensive experience in the biopharma industry, and our unique centres of excellence – for drug discovery in Berlin, formulation and GMP manufacturing in Sophia Antipolis, and our bioanalysis hub in Neu-Ulm – enable our experienced scientists to help guide and advance projects. We know how to discover, develop and bring the next generation of medicines to market. At the same time, we are committed to flexibility, transparency and collaboration in our approach, working closely with you to adapt to your individual needs, minimise risks and help deliver your project. Discovery: Helping you to achieve key decision milestones through deep scientific insights, innovation and collaboration. Preclinical: Enabling you to successfully develop and de-risk your preclinical candidates for a smooth transition to the clinic. CMC: Collaborating with you to advance molecules into drug products. Clinical: Providing tailored clinical solutions to fully assess your drug faster. Digital: Empowering your drug discovery and development with integrated data services, machine learning and generative AI. Research phases Supporting you with integrated, tailored solutions at every step of your drug discovery and development journey.
Nagi Bioscience
Nagi Bioscience is a pioneering high-tech Swiss company developing NextGen laboratory equipment to unlock the full potential of alternatives to animal testing with our patented Organism-on-Chip technology for high-content screening of drugs, chemicals, and other substances. Our technologies are accelerating drug development pipelines and introducing new toxicology testing standards revolutionizing pharmaceutical, biotech, food and nutrition, agro-chemical, cosmetic and animal health industries.
Molecule 46 s.r.o.
Molecule 46 is a biotech spin-off offering a unique patented technology for the separation of undamaged sperm to be used in human assisted reproduction and solve the infertility problem related to poor sperm quality. This technology is equally applicable to animal breeding strategies. The company brings an innovative approach with a strong IP position and robust scientific research. The new technology and clear regulatory pathway are strengthened by an internationally recognised founder with a strong academic track record and founder/market fit for a large and fast-growing market. Molecule 46 offers real social impact as well as endorsement from buyers and users. Our vision: Separation of winning sperm in alliance with nature. Our aim: Product certification and penetration to all the markets – European, American, and Global. | x
Menarini Biotech S.r.l.
Menarini Biotech (“MBH”) is a fast-growing, agile, fully integrated CDMO for biologics located in the greater Rome area, Italy. Established in 2003, Menarini Biotech’s mission is to provide fast and efficient, yet very customer-centric, world-class, high-quality, services for biotech companies from preclinical development to GMP manufacturing (Mammalian and Microbial) up to BSL-2. These include CHO cell line development and analytical development for standard and non-standard mAbs, and new molecular formats, e.g. bispecifics, ADCs, fusion proteins. Our Quality System complies with AIFA/EU GMP requirements.